Print
Email
Print Edition StoriesRib-X Pharmaceuticals Inc., an antibiotics company in New Haven, Conn., has begun a Phase 2b clinical trial of its treatments for acute bacterial skin and skin structure infections (ABSSSI).
The treatments – delafloxacin, linezolid and vancomycin – will be tested on 240 participants to help the company design Phase 3 clinical studies. The Phase 2b study is expected to show responses of the treatment on cellulitis/erysipelas, wound infection, major cutaneous abscess or burn infection.
The three drugs will also be measured as treatments for methicillin-resistant Staphylococcus aureus (MRSA).
“To complement this study, we plan to initiate a Phase 1 study later in the year to assess the Phase 3 oral formulation,” said Rib-X president and CEO Mark Leuchtenberger in a press release.
Last month, Rib-X submitted a regulatory filing, indicating that it had taken in $5.5 million of a planned $22 million offering combining debt, warrants and options.
Rib-X was founded in 2001 by Yale University colleagues Peter Moore, William Jorgensen and Thomas Steitz, winner of a portion of the 2009 Nobel Prize in Chemistry for his work describing the structure and function of the ribosome.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
